Similar results, defective NF-κB activation after FKBP51 depletion, were obtained in glioma [12], childhood acute lymphoblastic leukemia [9] and melanoma [8,49] after treatment with DNA damaging agents. This evidence concerns the gene FKBP4 and central nervous system cancer.